← All Pliant Therapeutics, INC filings

Pliant Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PLRX
Pliant Therapeutics, INC
10-K: Pliant Therapeutics Discontinues Phase 2b BEACON-IPF Trial Despite Early Efficacy Signals
Pliant Therapeutics halts its Phase 2b BEACON-IPF trial due to safety concerns, despite observing early signs of efficacy, and will reassess its development strategy.
NASDAQ
PLRX
Pliant Therapeutics, INC
10-K: Pliant Therapeutics Reports Full Year 2023 Results, Highlights Clinical Progress
Pliant Therapeutics' 2023 annual report details financial results and significant advancements in their clinical programs, particularly for bexotegrast.